Scorpius Holdings マネジメント

マネジメント基準チェック /44

Scorpius Holdingsの CEO はJeff Wolfで、 Aug2008年に任命され、の在任期間は 16.08年です。の年間総報酬は$ 575.00Kで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.58%を直接所有しており、その価値は€ 13.93K 。経営陣と取締役会の平均在任期間はそれぞれ5年と7.7年です。

主要情報

Jeff Wolf

最高経営責任者

US$575.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	16.1yrs
CEOの所有権	0.6%
経営陣の平均在職期間	5yrs
取締役会の平均在任期間	7.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Scorpius Holdings の収益と比較して、Jeff Wolf の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$575k	US$575k	-US$40m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$50m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$562k	-US$41m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$6m	US$540k	-US$35m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$6m	US$440k	-US$26m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$3m	US$428k	-US$20m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$1m	US$417k	-US$16m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$964k	US$417k	-US$12m

報酬と市場: Jeffの総報酬 ($USD 575.00K ) は、 German市場 ($USD 471.14K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jeffの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jeff Wolf (61 yo)

16.1yrs

在職期間

US$575,000

報酬

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D. founded Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) in August 2008 and has been Chairman...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
William Ostrander	CFO, Controller & Secretary	5yrs	US$375.00k	0.0010% € 24.7
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
George Peoples	Chief Medical Advisor	7.4yrs	データなし	データなし
Ania Szymanska	Site Head of Quality	less than a year	データなし	データなし
Joe Payne	President & COO of Scorpius BioManufacturing	less than a year	データなし	データなし

5.0yrs

平均在職期間

経験豊富な経営陣: 1HB0の経営陣は経験豊富で経験豊富です（平均在職期間は5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
John K. Prendergast	Independent Lead Director	8.4yrs	US$301.00k	0.038% € 916.3
John Monahan	Independent Director	14.8yrs	US$81.50k	0% € 0
Llew Keltner	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Anthony Tolcher	Scientific Advisory Board Member	6.5yrs	データなし	データなし
Roger Cohen	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Richard Myers	Chairman of BioThreat Advisory Board	2.3yrs	データなし	データなし
Gary Acton	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Robert Negrin	Member of Scientific Advisory Board	6.9yrs	データなし	データなし
Edward Smith	Independent Director	13.8yrs	US$92.50k	0% € 0
Robert Levy	Member of Scientific Advisory Board	6.9yrs	データなし	データなし

7.7yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: 1HB0の取締役会は経験豊富であると考えられます ( 7.7年の平均在任期間)。

Scorpius Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

New minor risk - Shareholder dilution

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold €169k worth of stock

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

New 90-day high: €11.05

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

New 90-day low: €0.79

New 90-day low: €0.81

Third quarter 2020 earnings released: US$0.062 loss per share

Revenue beats expectations

Revenue beats expectations

Third quarter 2020 earnings released: US$0.062 loss per share

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Earnings released

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44